A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

The main goal of this study is to test whether the study drug is safe and tolerable in patients with advanced/unresectable, or metastatic solid tumors (including small cell lung cancer, non-small cell lung cancer, esophageal squamous cell carcinoma, castration-resistant prostate cancer, and melanoma). This study will also measure the amount of the study drug in your blood at different time points, determine whether antibodies (proteins in your blood) against the study drug are produced in your body, and assess the effect of the study drug on your disease. In addition, this study may also explore the relationship between biomarkers (a biological molecule found in blood or tissue that may be a sign of a disease) in your body and the effect of the study drug on your disease.